Edition:
United States

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.95USD
23 May 2018
Change (% chg)

$0.00 (+0.52%)
Prev Close
$0.95
Open
$0.98
Day's High
$0.98
Day's Low
$0.95
Volume
36,199
Avg. Vol
49,666
52-wk High
$2.83
52-wk Low
$0.78

Select another date:

Tue, May 22 2018

BRIEF-Delmar Appoints Saiid Zarrabian Full-Time President And CEO

* DELMAR APPOINTS SAIID ZARRABIAN TO FULL-TIME PRESIDENT AND CEO

BRIEF-DelMar Pharmaceuticals Reports Q3 Loss Per Share Of $0.13

* DELMAR PHARMACEUTICALS ANNOUNCES THIRD QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM

BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share From 50 Mln Shares To 70 Mln Shares

* TO INCREASE NUMBER OF AUTHORIZED SHARES OF STOCK, PAR VALUE OF $0.001, PER SHARE FROM 50 MILLION SHARES TO 70 MILLION SHARES Source text: (https://bit.ly/2GWHkzx) Further company coverage:

BRIEF-Delmar Pharmaceuticals Q2 Loss Per Share $0.14

* DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

BRIEF-DelMar Pharmaceuticals Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma

* DELMAR PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR VAL-083 IN RECURRENT GLIOBLASTOMA

Select another date: